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Dysglycemia associations with adipose
tissue among HIV-infected patients after 2
years of antiretroviral therapy in Mwanza:
a follow-up cross-sectional study
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Abstract
Background: Data on the burden of dysglycemia among HIV-infected patients on antiretroviral therapy (ART) in Africa
are limited. We determined the prevalence of pre-diabetes and diabetes among HIV-infected patients who started ART
when malnourished 2 to 3 years previously and investigated the association of dysglycemia with body composition.
Methods: Malnourished (body mass index (BMI) < 18.5 kg/m2) HIV-infected patients who were enrolled in the
Nutritional Support for Africans Starting Antiretroviral Therapy (NUSTART) trial from 2011 to 2013 were followed-up
from March to August 2015. Anthropometric, fat mass and fat-free mass by bioelectrical impedance, and C-reactive
protein (CRP) data were collected at baseline and follow-up. At follow-up, we defined fasting glucose of 6.1–6.9 mmol/
L as impaired fasting glucose (IFG) and 2-h oral glucose tolerance test (OGTT) glucose of ≥7.8 to <11.1 mmol/L as
impaired glucose tolerance (IGT). Both of these were considered pre-diabetes. Fasting glucose of ≥7.0 mmol/L or
impaired glucose tolerance of ≥11.1 mmol/L was defined as diabetes mellitus. The relation of pre-diabetes and
diabetes with body composition was assessed using logistic regression.
Results: Two hundred seventy-three (57%) of 478 patients who were alive at trial conclusion were followed-up. The
mean age was 41.5 (SD 9.8) years and 65.2% (178) were females. The mean follow-up BMI was 19.9 (SD 2.8) kg/m2, 12
(4.4%) were either overweight or obese, and 61 (22.3%) patients had pre-diabetes or diabetes. In multiple regression,
upper tertiles of baseline hip circumference (OR: 0.41, 95% CI: 0.2, 0.8) and fat mass index (OR: 0.20 (0.1, 0.5), and upper
tertiles of follow-up waist circumference (OR: 0.22 (0.1, 0.5), BMI (OR: 0.32 (0.1, 0.7), fat mass index (OR: 0.19 (0.1, 0.5) and
the middle tertile of follow-up fat-free mass (OR: 0.36, 95% CI: 0.1, 0.8) were associated with lower risk of pre-diabetes and
diabetes (P < 0.05 for all). Baseline and follow-up CRP were not predictors.
Conclusions: Low rather than high measures of adipose tissue were associated with increased risk of pre-diabetes and
diabetes. Additional studies are needed to further investigate the role of body composition and control of glucose
metabolism in the pathogenesis of diabetes among persons living with HIV in Africa.
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Background
Diabetes mellitus is an emerging major public health prob-
lem in Africa [1] which has been associated with epidemio-
logic nutritional transition, globalization, and emergence of
infections like HIV [1, 2]. Data from developed countries
suggest that HIV-infected patients have a higher risk than
HIV-uninfected people of developing diabetes and other
non-communicable diseases [3, 4]. The excess diabetes risk
is probably related to multiple factors including HIV-
associated inflammation, the use of some antiretroviral
therapy (ART) regimens, and body composition changes
associated with HIV and ART [5, 6]. As a result, HIV-
infected populations may develop diabetes at a younger age
and may have a higher mortality if management is not
optimal, as may be the case in resource-limited countries of
Sub-Saharan Africa (SSA).
HIV immune activation and inflammation are hallmarks
of HIV pathogenesis and increase the risk of non-
communicable diseases including diabetes [7]. In guinea
pigs, pro-inflammatory cytokines such as tumor necrosis
factor (TNF)-alpha and interleukin 6 (IL-6) produced
during inflammation promote the release of free fatty acids
from adipose tissue which may reduce insulin action on
skeletal muscles resulting in dysglycaemia and diabetes
mellitus [8]. In SSA where HIV patients have multiple
opportunistic infections, including tuberculosis (TB), and
often start ART when they are very sick and have severe or
chronic inflammation, the risk is likely to be higher, but
data are limited. The use of some ART regimens may in-
crease diabetes risk [3, 4] through mitochondrial toxicity of
skeletal muscle and adipose tissues. The problem may be
greater in SSA than in high income countries since older
ART drugs which have higher levels of toxicity are often
still used in SSA.
Furthermore, HIV-infected patients who may have
started ART with low body mass index (BMI) [9] will
rapidly regain weight once on ART; however, this weight
increment may mainly comprise adipose tissue rather than
lean mass since persistent inflammation limits regain of
lean mass [10, 11] This excessive increment in adipose
tissue relative to lean mass may increase the risk of
diabetes mellitus.
Most of the data to-date on HIV and diabetes are from
high-income countries, and data in SSA are few and incon-
sistent [12–14]. Because of differences in genetic compos-
ition as well as environmental factors including high
burden of infectious diseases in resource-limited settings,
data from high-income countries cannot be extrapolated
and reliably used to improve quality of diabetes care among
HIV patients in SSA. It is therefore crucial that HIV
programmes in SSA, where the majority of HIV-infected
patients in the world reside, get data on the magnitude of
and risk factors for diabetes among HIV-infected patients
to help plan for prevention and treatment interventions.
Therefore, we followed-up HIV-infected patients who were
malnourished when they enrolled 2–3 years previously in
the Nutritional Support for Africans Starting Antiretroviral
Therapy (NUSTART) trial [15]. We determined in these
patients the prevalence of pre-diabetes and diabetes and
investigated associations with anthropometric and body
composition measurements on the background of very high
HIV-associated inflammation [16].
Methods
Study design and setting
This was a follow-up cross-sectional study conducted from
March to August 2015 at the National Institute for Medical
Research (NIMR), Mwanza, in north-western Tanzania.
Participants were eligible if they had been recruited in the
NUSTART trial and provided informed consent for this
follow-up study which included consent to use their NUS-
TART data for this study. NUSTART was a phase III ran-
domized controlled trial testing the efficacy of vitamins and
minerals in a lipid-based supplement on morbidity and
mortality of malnourished (BMI < 18.5 kg/m2) HIV-
infected patients starting ART and was conducted in
Lusaka, Zambia and Mwanza, Tanzania from August 2011
to December 2013 [15]. Enrolment and exclusion criteria
and other study details have been published previously [15].
The current study sought follow-up of all participants who
completed the NUSTART study in Mwanza (12 weeks
post-ART initiation), 2–3 years later.
Study participants follow-up strategy
To maximise follow-up of participants, all patients who
were known to be alive at the end of the NUSTART trial
were telephoned several times to introduce them to the
follow-up study, to determine if they were interested, and
to make an appointment. Potential participants who were
not reachable by phone were visited at home and invited to
join the study. If patients were not available to respond to
the call or talk with the study tracer during home visits, we
requested people responding to the call or those found in
participants’ homes to provide information on participants’
vital status and if they had travelled or relocated perman-
ently from the Mwanza city. Patients given clinic visit ap-
pointments were requested to come to the NIMR Research
Clinic in Mwanza City at 8:00 am after an overnight fast of
at least 8 h to receive further study information, and for
consenting and study procedures.
Data collection
Before study data collection began, research assistants
were recruited and trained on standard operating proce-
dures for consenting, questionnaire administration, blood
sampling, and glucose testing and interpretation.
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Questionnaire data
Questionnaire data were collected using structured inter-
views. Based on WHO STEPS manual questionnaire [17],
information on demography, education level, occupation, re-
ligion, marital status, smoking, alcohol use, fruit and vege-
table consumption, and level of physical activity. We used
show cards in the WHO STEPS manual [17] to assist data
collection. For alcohol and smoking, the key questions were
whether patients had ever taken alcohol and/or smoked and
if they were current alcohol drinkers and/or smokers. Taking
alcohol in the past 30 days was considered current alcohol
drinking and patients who reported to have ever smoked
and had not stopped smoking at the time of the study were
considered current smokers. Fruit and vegetable intake was
assessed based on consumption history in the past
12 months. To help patients remember what they usually
eat and amounts, we prepared a list of commonly available
fruits and vegetables in Mwanza and provided a container
for them to estimate the quantity of fruits and vegetables
they are taking on days they reported to be eating fruits and
vegetables. Using this information, a trained research assist-
ant converted the quantities ingested into servings; with one
serving weighing approximately 80 g. We also collected in-
formation on ART use history and adherence, TB treatment
history from NUSTART enrolment, and symptoms of dia-
betes. Information on ART use history was verified through
patients’ARTcards and ARTclinic records.
Glucose testing
Before glucose testing, the research assistant asked patients
if they had taken any food except water (fasted) for at least
8 h before visiting the clinic. Those fasting were finger
pricked to provide blood for glucose measurement using a
Hemocue machine (Hemocue AB, Angelholm, Sweden).
After fasting glucose assessment, all patients were subjected
to a 2-h oral glucose tolerance test (OGTT) where they
were provided with 82.5 g of dextrose monohydrate
(equivalent to 75 g of glucose anhydrous) diluted in 250
mls of drinking water to drink within 5 min. The OGTT
glucose assessment was done 2 h later. Based on WHO
guidelines [18], patients whose fasting glucose ranged be-
tween 6.1 and 6.9 mmol/L were diagnosed with impaired
fasting glucose (IFG) whereas those with OGTT glucose
level of ≥7.8 to <11.1 were diagnosed with impaired glucose
tolerance (IGT). Patients with either IFG or IGT were clas-
sified as having pre-diabetes, a condition associated with
higher risk of developing diabetes mellitus [19]. Diabetes
mellitus was defined as fasting glucose of ≥7.0 mmol/L or
impaired glucose tolerance of ≥11.1 mmol/L.
Blood for C-reactive protein (CRP)
Venous blood samples were collected and centrifuged for
serum CRP testing by ELISA (AssayPro, St. Charles, MO,
USA) in the NIMR, Mwanza immunology laboratory.
Retrieval of NUSTART data
As part of this study, we retrieved and used NUSTART
trial data. Data used include baseline socio-economic
status, trial enrolment date, ART start date, baseline CD4
count, TB treatment history at trial enrolment, baseline
log-transformed CRP data, baseline fat and fat free mass
indices measured by bioelectrical impedance analysis
(BIA), and baseline waist and hip circumferences.
Follow-up anthropometry and body composition data
During the current study, we determined anthropomet-
ric measurements using standardized methods. While
barefoot and with minimal clothing, weight of the pa-
tient was determined to the nearest 0.1 kg using a digital
scale (Seca, Germany) and height was measured to the
nearest 0.1 cm using a stadiometer fixed to the office
wall (Seca, Germany). Waist and hip circumferences
were measured using non-stretchable tape (to 1 mm).
Anthropometric measurements were taken in triplicate
and medians were used during analysis. Also similar to
NUSTART baseline [10], participants underwent BIA to
estimate fat mass and fat-free mass (Tanita BC418,
Tokyo, Japan). Since internal equations in the BIA Tanita
machine were derived from studies of predominantly
non-malnourished populations, and may not account for
differences in hydration status and other factors present
in malnourished, HIV-infected individuals [20], plet-
hysmography data (BodPod 2007A, Life Measurement
Instruments/COSMED, California, USA) collected at
NUSTART baseline in a sub-sample of Zambian patients
were used to adjust the BIA calculations for baseline and
follow-up data to account for changes in body compos-
ition unique to this patient population. The adjustment
was done using BodPod since BodPod data are more
likely to be accurate and precise than BIA data in mal-
nourished populations [21]. In the calibration, regression
analysis was used to develop an optimal equation to
predict BodPod fat-free mass with BIA Impedance index
(height squared/whole body impedance), weight, height
and sex as dependant variables. Based on this, the final
adjusted BIA fat-free mass data were compiled using this
equation: Fat-free mass = −5.951 + (height squared/whole
body impedance × 0.292) - (female sex × 1.345)
+ (weight × 0.324) + (height × 0.128) (Wells JCK and
Woodd S, unpublished data). The method used was
similar to that used in validating BIA against Bodpod
among Ethiopian infants [22]. Subsequently fat mass was
computed as: weight minus fat-free mass. From BIA fat
and fat-free mass, and height measurements, fat mass
index was computed as fat mass (kg)/[height (m2)], and
fat-free mass index as fat-free mass (kg)/[height (m2)]
[23]. We used fat mass and fat-free mass indices in-
stead of fat and fat-free mass to remove the effect of
variability in size.
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Sample size
The sample size for this study was based on the conven-
tional formula for the confidence interval around an Odds
Ratio for the increased odds of pre-diabetes and diabetes
(main outcome) [24]. Based on previous studies, we antici-
pated that at least 20% of ART patients would have a high
level of inflammation, and 20% would have excessive
deposition of adipose tissue (the two main risk factors),
and that 10% of the patients would have pre-diabetes or
diabetes. We aimed to trace 60% of 478 of surviving
patients from the NUSTART study, and with a sample size
of 50 patients with pre-diabetes or diabetes and 200
patients without, the study would have 90% power to
detect an Odds Ratio of 4 as significant at the 5% level.
Data management and statistics
Data were double entered into OpenClinica database and
analysed in STATA version 12 (Station College, Texas,
USA). Cohort characteristics were presented as means or
percentages as appropriate. Comparisons of followed-up pa-
tients versus those not followed-up (either died or lost to
follow-up) were done using t-test and oneway ANOVA for
continuous variables and chi-squared test for categorical var-
iables. For continuous variables with >2 comparison groups,
Bonferroni post hoc test was used to determine difference
between group pairs after oneway ANOVA was done.
Combined pre-diabetes and diabetes was the outcome
variable whereas baseline and follow-up body compos-
ition parameters (fat and fat-free mass indices), BMI,
waist and hip circumferences, and log-transformed base-
line and follow-up CRP were considered the main pre-
dictor variables. Demography, socio-economic status, TB
treatment at NUSTART trial enrolment, TB treatment
history at follow-up, smoking, alcohol drinking, fruit and
vegetable intake, and ART regimens used were included
in models as potential confounders. Univariate logistic
regression was conducted for all predictor variables and
potential confounders whose effect sizes were significant
at P < 0.10 were adjusted for in multiple logistic regres-
sion models assessing the relationship between the out-
come variable and main predictor variables. To avoid
the effect of multicollinearity, we included only one an-
thropometric or body composition explanatory variable
in these models at a time. To enhance clarity in data
presentation, main analysis included anthropometric and
body composition measurements as tertiles rather than
continuous variables. In supplementary analyses we in-
cluded anthropometric and body composition measure-
ments in a continuous scale as predictor variables and
assessed the role of body composition changes on the
study outcome. The effect sizes were presented as odds
ratios (OR) with 95% confidence intervals. P values
<0.05 indicated significant differences.
Results
Characteristics of followed-up patients compared to those
not followed-up
Figure 1 shows participants flow from NUSTART trial
enrolment until the current study. Of 704 patients en-
rolled in NUSTART trial, 478 patients were alive at
12 weeks ART, i.e., the end of NUSTART trial follow-up,
273 (38.8%) were followed-up 2 to 3 years later, 286
(40.6%) had died either during or after NUSTART, and
145 (20.6%) were either lost to follow-up, had travelled
out of Mwanza city or declined to participate. Baseline
measures of both BMI and fat mass index were lower
among patients who died before follow-up compared to
those followed-up and there were differences among the
Fig. 1 Participant flow chart
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three groups in sex, education attainment, CD4 count, and
TB treatment history at NUSTART enrolment (Table 1).
Characteristics of followed-up patients
The 273 patients followed up were seen 31 months
(range 21 to 42) from NUSTART recruitment. As seen
in Table 2, among these patients, the mean follow-up
BMI was 19.9 (SD 2.8) kg/m2, 12 (4.4%) were either
overweight or obese, 11 (4%) were current smokers, 31
(11.4%) were current alcohol drinkers, 113 (41.4%) had
adequate (≥5 servings per day) fruit and vegetable con-
sumption, 260 (95.2%) reported they were currently on
ART and 209 (76.6%) patients spent >75 min in vigorous
physical activity per week. On average these patients had
Table 1 Comparison of NUSTART recruitment characteristics of patients followed-up at 2–3 years post-ART initiation versus those
not followed-up (due to loss to follow-up, lack of data or death)a
Followed-up at
2–3 years post ART (n = 273)
Lost to follow-up or died before 2–3 years-post ART (n = 431) P-valueb
Lost to follow-up (n = 145) Died (n = 286)
Age at baseline, year 38.9 (9.7) 35.9 (9.7) 38.3 (9.9) 0.01e
Female, n (%) 178 (65.2) 76 (52.4) 133 (45.6) <0.0001
Marital status, n (%)c
Married 122 (44.7) 48 (33.3) 114 (39.9) 0.16
Widow/widower 38 (13.9) 17 (11.8) 40 (14.0)
Divorced/separated 94 (34.4) 59 (41.0) 96 (33.5)
Single 19 (7.0) 19 (13.2) 34 (11.9)
Lives with partner 0 (0.0) 1 (0.7) 2 (0.7)
Occupation, n (%)c
Salaried 6 (2.2) 8 (5.6) 10 (3.5) 0.16
Self-employed 237 (86.8) 119 (82.6) 251 (87.8)
Housewife 19 (7.0) 6 (4.1) 10 (3.5)
Student 2 (0.7) 3 (2.1) 1 (0.3)
Unemployed 9 (3.3) 8 (5.6) 14 (4.9)
Education level, n (%)c
None 81 (29.6) 31 (21.5) 82 (28.7) 0.01
Primary 176 (64.5) 104 (72.2) 192 (67.1)
Secondary 16 (5.9) 5 (3.5) 11 (3.9)
University/Tertiary 0 (0) 4 (2.8) 1 (0.3)
Social economic status, n (%)
Lowest 58 (21.3) 19 (13.1) 64 (22.4) 0.10
Low 64 (23.4) 24 (16.6) 62 (21.7)
Middle 54 (19.8) 28 (19.3) 50 (17.5)
High 47 (17.2) 39 (26.9) 55 (19.2)
Highest 50 (18.3) 35 (24.1) 55 (19.2)
Fat mass index (kg/m2)d 2.9 (0.8) 2.7 (0.8) 2.5 (0.8) <0.0001f
Fat-free mass index (kg/m2)d 14.0 (0.9) 14.1 (0.8) 13.9 (1.0) 0.14
Body mass index (kg/m2) 16.7 (1.2) 16.7 (1.2) 16.2 (1.5) 0.0001g
CD4 count (cells/μL) 127 (99.7) 116 (102.8) 113 (106.8) 0.29
Tuberculosis treatment, n (%) 63 (23.1) 49 (33.8) 48 (16.8) <0.0001
aData are mean ± SD unless specified as n (%)
bcomparison done by oneway ANOVA test for continuous outcomes and chi-squared test for categorical outcomes
c1 patient missing in the lost-to follow-up group
d25 patients in the followed-up group, 16 in the lost to follow-up group, and 68 in the died group missing
eBonferroni test showed differences between the followed-up group and the lost to follow-up group (P = 0.009) and the lost to follow-up group and the died
group (P = 0.049)
fBonferroni test showed differences between the followed-up group and the died group (P < 0.0001)
gBonferroni test showed differences between the followed-up group and the died group (P < 0.0001) and the lost to follow-up group and the died
group (P < 0.0001)
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been on ART for a total of 30 months (range 20 to 41)
and on the current ART regimens for 19 months (range
16.5 to 41). Regarding dysglycaemia, 61 (22.3%) patients
had either pre-diabetes or diabetes. Those with pre-
diabetes and diabetes had lower body weight, fat mass
index, BMI, and waist and hip circumferences compared
to those with no pre-diabetes and diabetes, but there
were no differences in clinical presentation (Additional
file 1: Table S1). Among the followed-up patients, the
mean fat mass index and fat-free mass index increased
from 2.8 kg/m2 and 14.0 kg/m2 at baseline by 2.0 kg/m2
and 1.0 kg/m2 by 2–3 years follow-up (P <0.0001 for all).
Predictors of pre-diabetes and diabetes
In univariate logistic regression (Table 3), higher socioeco-
nomic status, higher fruit and vegetable intake, and history
of TB treatment since NUSTART recruitment were associ-
ated with lower probabilities of having pre-diabetes and dia-
betes; similar trends towards lower diabetes and pre-diabetes
were seen in patients who reported to be on TB treatment at
NUSTART baseline and those who were current alcohol
drinkers. Baseline and follow-up CRP, baseline CD4 count,
and current ART regimens were not predictors. Higher base-
line hip circumference and fat mass index, and higher
follow-up waist and hip circumferences, and body mass and
fat mass indices were associated with lower probabilities of
having pre-diabetes and diabetes (P < 0.005 for all).
As seen in Table 4, in multiple regression models ad-
justed for age, sex, socioeconomic status, and baseline TB
treatment, higher baseline hip circumference and fat mass
index were associated with lower probability of having
pre-diabetes and diabetes. At follow-up, the main pre-
dictor variables were adjusted for age, sex, socioeconomic
status, history of TB treatment since baseline, alcohol
drinking and vegetable and fruit intake. In these models,
higher waist or hip circumference, BMI, fat mass index
and fat-free mass index were associated with lower prob-
abilities of having pre-diabetes and diabetes (P < 0.05 for
all except hip circumference where P = 0.08). Baseline fat-
free mass index was not associated with the study out-
come, and baseline and follow-up CRP were not included
in the multiple regressions because they were not predic-
tors in univariable analysis. The results showed similar
trends when body composition data were included as pre-
dictors in a continuous scale (Additional file 2: Table S2
and Additional file 3: Table S3) and additional analyses in-
volving changes in anthropometric and body composition
measurements as predictor variables ended with similar
results as main analyses (Additional file 4: Table S4 and
Additional file 5: Table S5).
Discussion
In this report we present results of follow-up evaluation of
dysglycaemia among patients who were enrolled in the
Table 2 Characteristics at follow-up of 273 patients included in
the studya
Age at follow-up, year 41.5 (9.8)
(Range 21–75)
Religion
Christian 225 (82.4)
Muslim 34 (12.5)
No religion 14 (5.1)
Smoking status, n (%)
Never 197 (72.2)
Past 65 (23.8)
Current 11 (4.0)
Alcohol drinking, n (%)b
Never 108 (39.7)
Past 133 (48.9)
Current 31 (11.4)
Fruits and vegetables consumption per day, n (%)
1–2 servings 81 (29.7)
3–4 servings 79 (28.9)
≥ 5 servings 113 (41.4)
Time spent in vigorous physical activity per week (minutes), n (%)
Inadequate (<75 min) 64 (23.4)
Adequate (≥75 min) 209 (76.6)
Weight (kg) 52.8 (8.5)
Body mass index (kg/m2) 19.9 (2.8)
Nutritional status according to BMI categories, n (%)
Undernourished (BMI < 18.50 kg/m2) 73 (26.7)
Normal weight (BMI 18.50–24.99 kg/m2) 188 (68.9)
Overweight (BMI 25.00–29.99 kg/m2) 10 (3.7)
Obese (BMI ≥ 30.00 kg/m2) 2 (0.7)
Fat mass index (kg/m2)c 4.3 (2.4)
Fat-free mass index (kg/m2)c 15.5 (1.6)
Current antiretroviral therapy regimen, n (%)d
AZT + 3TC + EFV 41 (15.8)
AZT + 3TC + NVP 84 (32.3)
TDF + FTC + EFV 70 (26.9)
TDF + 3TC + EFV 65 (25.0)
Pre-diabetes, n (%)e 57 (20.8)
Diabetes Mellitus, n (%) 4 (1.5)
Pre-diabetes (IFG + IGT) and Diabetes Mellitus, n (%) 61 (22.3)
AZT Zidovudine, 3TC Lamivudine, EFV Efavirenz, NVP Nevirapine, TDF Tenofovir,
FTC Emtricitabine
aData in mean(sd) or n (%)
b272 patients included in analysis
c269 patients included in analysis
d260 patients included in analysis
eImpaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT)
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Table 3 Univariate analysis of socio-demography, alcohol drinking, smoking, fruit and vegetable intake, physical activity, and body
composition as predictors for pre-diabetes and diabetes at 2 to 3 years post-ART
PD/DM+a
(n = 61)
PD/DM-b
(n = 212)
Odds Ratio
(95% CI)
P-value
n(%) or mean (sd) n(%) or mean (sd)
Age at follow-up, years 41.8 (7.9) 41.4 (10.3) 1.00 (0.9–1.0) 0.76
Sex
Male 24 (39.3) 71 (33.5) Reference 0.40
Female 37 (60.7) 141 (66.5) 0.78 (0.4, 1.4)
Marital status
Married/cohabiting 26 (42.6) 104 (49.1) Reference 0.59
Widow/widower 9 (14.7) 36 (16.9) 1.00 (0.4, 2.3)
Separated/divorced 22 (36.1) 57 (26.9) 1.54 (0.8, 2.9)
Single 4 (6.6) 15 (7.1) 1.07 (0.3, 3.5)
Occupation
Self-employed 51 (83.6) 181 (85.4) Reference 0.41
Salaried 3 (5.0) 12 (5.7) 0.89 (0.2, 3.2)
Housewife 1 (1.6) 9 (4.2) 0.39 (0.05,3.2)
No employment/other 6 (9.8) 10 (4.7) 2.13 (0.7, 6.1)
Highest education level
Never attended school 18 (29.5) 60 (28.3) Reference 0.96
Primary 40 (65.6) 139 (65.5) 0.95 (0.5, 1.8)
Secondary 3 (4.9) 12 (5.7) 0.83 (0.2, 3.2)
Vocational college/Tertiary 0 (0) 1 (0.5) –
Social economic status
Lowest 15 (24.6) 43 (20.3) Reference 0.03
Low 22 (36.0) 42 (19.8) 1.50 (0.6, 3.3)
Middle 10 (16.4) 43 (20.3) 0.67 (0.3, 1.6)
High 4 (6.6) 44 (20.7) 0.26 (0.1, 0.8)
Highest 10 (16.4) 40 (18.9) 0.71 (0.3, 1.8)
Alcohol drinking
Never 31 (51.7) 77 (36.3) Reference 0.06
Past 26 (43.3) 107 (50.5) 0.60 (0.3, 1.1)
Current 3 (5.0) 28 (13.2) 0.27 (0.1, 0.9)
Smoking status
Never 45 (73.8) 152 (71.7) Reference 0.92
Past 14 (22.9) 51 (24.1) 0.93 (0.5, 1.8)
Current 2 (3.3) 9 (4.2) 0.75 (0.2, 3.6)
Fruits and vegetables intake per day
1–2 servings 26 (42.6) 55 (25.9) Reference 0.04
3–4 servings 15 (24.6) 64 (30.2) 0.49 (0.2, 1.0)
≥ 5 servings 20 (32.8) 93 (43.9) 0.45 (0.2, 0.9)
Time spent in vigorous physical activity per week (minutes)
Inadequate (<75 min) 13 (21.3) 51 (24.1) Reference 0.66
Adequate (≥75 min) 48 (78.7) 161 (75.9) 1.17 (0.6, 2.3)
Months on ARTc 30 (4.5) 31 (5.2) 0.98 (09, 1.0) 0.57
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Table 3 Univariate analysis of socio-demography, alcohol drinking, smoking, fruit and vegetable intake, physical activity, and body
composition as predictors for pre-diabetes and diabetes at 2 to 3 years post-ART (Continued)
Current ART regimen
AZT + 3TC + EFV 9 (15.3) 32 (15.9) Reference 0.92
AZT + 3TC + NVP 20 (33.9) 64 (31.8) 1.11 (0.5, 2.7)
TDF + FTC + EFV 14 (23.7) 56 (27.9) 0.89 (0.3, 2.3)
TDF + 3TC + EFV 16 (27.1) 49 (24.4) 1.16 (0.5, 2.9)
TB treatment at baseline
Did not receive TB treatment 52 (85.3) 158 (74.5) Reference 0.08
Received TB treatment 9 (14.7) 54 (25.5) 0.50 (0.2, 1.1)
TB treatment since baseline
Did not receive TB treatment 50 (82.0) 146 (68.9) Reference 0.048
Received TB treatment 11 (18.0) 66 (31.1) 0.48 (0.2, 0.9)
Baseline CD4 count (cells/μL) 127 (104) 127 (98) 0.99 (0.9, 1.0) 0.99
Baseline CRP
(Log -transformed)d
3.7 (1.7) 3.7 (1.8) 0.99 (0.8, 1.2) 0.91
Follow-up CRP
(Log -transformed)
1.8 (1.6) 1.5 (1.4) 1.16 (0.9, 1.4) 0.14
NUSTART intervention assignment
Control arm 30 (49.2) 98 (46.2) Reference 0.68
Treatment arm 31 (50.8) 114 (53.8) 0.89 (0.5, 1.6)
Baseline anthropometrics and body composition
Waist circumference tertiles
Lower 13 (21.3) 51 (24.1) Reference 0.18
Middle 27 (44.3) 67 (31.6) 1.58 (0.7, 3.4)
Upper 21 (34.4) 94 (44.3) 0.87 (0.4, 1.9)
Hip circumference tertiles
Lower 23 (37.7) 45 (21.2) References 0.03
Middle 18 (29.5) 68 (32.1) 0.52 (0.3, 1.1)
Upper 20 (32.8) 99 (46.7) 0.39 (0.2, 0.8)
Body mass index tertiles
Lower 16 (26.2) 50 (23.6) Reference 0.78
Middle 21 (34.5) 68 (32.1) 0.96 (0.5, 2.0)
Upper 24 (39.3) 94 (44.3) 0.79 (0.4, 1.6)
Fat mass index tertilese
Lower 23 (41.8) 41 (21.2) Reference 0.007
Middle 17 (30.9) 66 (34.2) 0.46 (0.2, 0.9)
Upper 15 (27.3) 86 (44.6) 0.31 (0.1, 0.7)
Fat-free mass index tertilese
Lower 18 (32.7) 64 (33.2) Reference 0.67
Middle 17 (30.9) 70 (36.2) 0.86 (0.4,1.8)
Upper 20 (36.4) 59 (30.6) 1.21 (0.6, 2.5)
Follow-up anthropometrics and body composition
Waist circumference tertiles
Lower 32 (52.5) 61 (28.8) Reference 0.0008
Middle 20 (32.8) 71 (33.5) 0.53 (0.3, 1.0)
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NUSTART trial 2–3 years earlier. Due to high mortality
and loss to follow-up, we managed to assess 273 of 478
patients (57%) who were alive at trial conclusion (12 weeks
post-ART initiation), which was 38% of 704 patients who
were enrolled in the trial. In these patients, the prevalence
of pre-diabetes and diabetes was 22%, and this was associ-
ated with lower fat mass at both ART referral and follow-
up. Although frank diabetes was only about 1.5%, the
prevalence of pre-diabetes comprising either impaired
fasting glucose or impaired glucose tolerance was over
20%. Pre-diabetes is associated with an elevated risk of
cardiovascular disease and of mortality [25–28], and in
HIV-uninfected western populations 50% of patients with
pre-diabetes develop diabetes in the span of 10 years or
less [29]. Information as to whether this rapid progression
from pre-diabetes to diabetes will be seen in resource-
limited, high-HIV prevalence settings is lacking.
In this study, we hypothesized that excessive accumu-
lation of adipose tissue occurring during ART on the
background of high and persistent inflammation would
be associated with pre-diabetes and diabetes. Although
patients who were followed-up accumulated more adi-
pose tissue relative to lean mass, it was patients who had
lower baseline and follow-up fat mass rather than those
with higher baseline and follow-up fat mass who were
found to have pre-diabetes and diabetes. Unexpectedly,
we did not see any effect of baseline or follow-up CRP
on the study outcome in this followed-up cohort.
Several mechanisms may explain our unexpected findings.
Since low fat mass or BMI is a marker of severe or pro-
longed HIV infection [30, 31], our results may suggest that
pre-diabetes and diabetes occurred among malnourished pa-
tients who were severely immune-compromised or those
with severe immune activation and that those who were less
immune-compromised were spared. Patients with prolonged
HIV immune activation, may have insulin resistance, and
may subsequently develop pre-diabetes or diabetes mellitus
[8]. However, we found no evidence that CRP (the marker
of inflammation and immune activation used in this study)
was associated with pre-diabetes and diabetes. Similarly,
CD4 count (used to assess severity of HIV because HIV viral
loads were not routinely measured in Tanzania) was not a
predictor of pre-diabetes and diabetes. Another possibility is
that we observed a variant of pre-diabetes and diabetes mel-
litus which is associated with nutritional deprivation rather
than over nutrition. In Ethiopia, investigators found that
compared to non-diabetes patients, diabetic patients receiv-
ing insulin were more likely to have low weight and height
(if men) and low socioeconomic status and were more likely
to have been undernourished during childhood than non-
Table 3 Univariate analysis of socio-demography, alcohol drinking, smoking, fruit and vegetable intake, physical activity, and body
composition as predictors for pre-diabetes and diabetes at 2 to 3 years post-ART (Continued)
Upper 9 (14.7) 80 (37.7) 0.21 (0.1, 05)
Hip circumference tertiles
Lower 30 (49.2) 62 (29.3) Reference 0.007
Middle 20 (32.8) 73 (34.4) 0.56 (0.3, 1.1)
Upper 11 (18.0) 77 (36.3) 0.29 (0.1, 0.6)
Body mass index tertiles
Lower 30 (49.2) 61 (28.8) Reference 0.009
Middle 18 (29.5) 73 (34.4) 0.50 (0.3, 0.9)
Upper 13 (21.3) 78 (36.8) 0.34 (0.2, 0.7)
Fat mass index tertilesf
Lower 33 (55.0) 57 (27.3) Reference 0.0003
Middle 17 (28.3) 73 (34.9) 0.40 (0.2, 0.8)
Upper 10 (16.7) 79 (38.7) 0.21 (0.1, 0.5)
Fat-free mass index tertilesf
Lower 26 (43.3) 64 (30.6) Reference
Middle 13 (21.7) 77 (36.8) 0.41 (0.2, 0.9) 0.07
Upper 21 (35.0) 68 (32.6) 0.76 (0.4, 1.5)
ART antiretroviral therapy, AZT, Zidovudine, 3TC Lamivudine, EFV Efavirenz, NVP, Nevirapine, TDF Tenofovir, FTC Emtricitabine
aPatients with Pre-diabetes and diabetes
bPatients without pre-diabetes and diabetes
cPD/DM+ patients were 58 and PD/DM- patients were 194
dPD/DM+ patients were 53 and PD/DM- patients were 193
ePD/DM+ patients were 53 and PD/DM- patients were 193
fPD/DM+ patients were 60 and PD/DM- patients were 209
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diabetics [32]. Similar findings have been reported in other
settings [33, 34], and this variant of diabetes has been
termed as malnutrition-related diabetes mellitus (MRDM).
MRDM may occur in individuals with long standing malnu-
trition and is characterized by insulinopenia, insulin resist-
ance and failure of beta-cell function resulting from
irreversible pancreatic injury associated with pancreatic cal-
culi formation [35]. Although there are little or no data on
the effect of HIV-related prolonged undernutrition on
diabetes risk, it is conceivable that severe nutritional deple-
tion as occurred among patients who were eligible for the
NUSTART trial could have led to pancreatic injury and con-
sequently compromised beta-cell function leading to dysgly-
caemia presented in this study. Both Impaired Fasting
Glucose (IFG) and Intolerance Glucose Tolerance (IGT)
which are the basis for diagnosis of pre-diabetes and dia-
betes result from insulin resistance (hepatic and skeletal in-
sulin resistance, respectively) and reduced insulin secretion
[36–38]. Furthermore, since pre-diabetes and diabetes was
associated with reduced rather than increased adipose tissue,
it is likely that reduced insulin secretion due to MRDM ra-
ther than insulin resistance explains most the associations
we present. However, detailed mechanistic studies are
needed to explain well these observations.
The reported prevalence of pre-diabetes and diabetes in
the current study is comparable with other reports of stud-
ies in Sub-Saharan Africa [39–41], but lower than what was
recently reported in Mwanza by Maganga et al. [13]. In the
latter study, investigators reported that the prevalence of
pre-diabetes and diabetes among HIV-infected patients was
32.7% and that 18% of patients who had been on ART for
at least 2 years had frank diabetes mellitus. We see at least
one key methodological attribute which could explain the
difference in these findings from the current study. The
study population of Maganga et al. was drawn from the
general HIV population with mean BMI at ART initiation
of 22 kg/m2, whereas our study participants comprised in-
dividuals who started ART with BMI of <18.5 kg/m2, the
level of BMI associated with higher mortality during ART
[9]. Because the NUSTART participants who died before
the current study had lower fat mass and BMI at ART initi-
ation, and these are associated with increased risk of pre-
diabetes and diabetes, it is possible that a higher proportion
of deaths occurred among patients with pre-diabetes and
diabetes compared to patients with normal glucose levels.
This is plausible considering that high glucose level is also
associated with elevated mortality [28, 42]. If this occurred,
it would help explain a lower prevalence of pre-diabetes
and diabetes among patients we followed-up in comparison
to the recent report [13]. Irrespective of reasons explaining
differences in these results, it is clear that the burden of
pre-diabetes and diabetes among HIV-infected patients in
Tanzania is very high and the Tanzanian Ministry of Health
should develop strategies to reduce diabetes risk among
Table 4 Multivariable analysis of anthropometric and body
composition measurements as predictors for pre-diabetes and
diabetes at 2 to 3 years post-ART
Adjusted Odds Ratio (95% CI) P-value
Baseline anthropometrics and body compositiona
Waist circumference tertiles
Lower Reference 0.19
Middle 1.49 (0.7, 3.3)
Upper 0.79 (0.4, 1.8)
Hip circumference tertiles
Lower Reference 0.05
Middle 0.57 (0.3, 1.2)
Upper 0.41 (0.2, 0.8)
Fat mass index tertiles
Lower Reference 0.002
Middle 0.30 (0.1, 0.7)
Upper 0.20 (0.1, 0.5)
Fat-free mass index tertiles
Lower Reference 0.73
Middle 0.79 (0.4,1.7)
Upper 0.70 (0.3, 1.8)
Follow-up anthropometrics and body compositionb
Waist circumference tertiles
Lower Reference 0.003
Middle 0.58 (0.3, 1.2)
Upper 0.22 (0.1, 0.5)
Hip circumference tertiles
Lower Reference 0.08
Middle 0.67 (0.3, 1.4)
Upper 0.39 (0.2, 0.9)
Body mass index tertiles
Lower Reference 0.01
Middle 0.46 (0.2, 1.00
Upper 0.32 (0.1, 0.7)
Fat mass index tertiles
Lower Reference 0.0008
Middle 0.39 (0.2, 0.8)
Upper 0.19 (0.1, 0.5)
Fat-free mass index tertiles
Lower Reference 0.05
Middle 0.36 (0.1, 0.8)
Upper 0.62 (0.3, 1.3)
aAnalyses adjusted for age, sex, socio-economic status, and history of TB
treatment at baseline
bAnalyses adjusted for age, sex, socio-economic status, history of TB treatment
since baseline, alcohol drinking, and vegetable and fruit intake
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patients on ART and provide appropriate care to those de-
veloping frank diabetes to reduce the risk of mortality and
the complications of diabetes. Other countries in the region
may be similarly affected, and should consider prevention,
screening, and treatment programs as well.
The prevalences of most traditional diabetes risk fac-
tors were low in our study population. The prevalence of
overweight and obesity was only 4.4%, and that of
current smoking was 4%. In addition, more than three
quarters of patients spent more than 75 min in vigorous
physical activity per week, which is an adequate level of
physical activity according to WHO [43]; all patients had
more than the WHO recommended level of moderate
activity, so this was not included as a risk factor in ana-
lyses. However, we found that only 41% of study partici-
pants had adequate intake of fruit and vegetables.
Although intake of fruits and vegetables was not a pre-
dictor of pre-diabetes and diabetes in multivariable ana-
lysis (data not shown), promotion of fruit and vegetable
intake among HIV-infected patients should be included
in chronic disease reduction programs as it might help
to reduce the risk of other non-communicable diseases
related to diabetes in these patients [44, 45]. CD4 count
at referral to ART and use of particular ART regimens
were not associated with pre-diabetes and diabetes.
Regarding socio-economic status, we found that lower
socioeconomic class seemed to be significantly associ-
ated with higher risk of pre-diabetes and diabetes in un-
adjusted analysis.
This is similar to findings in other African settings. In
Ethiopia, investigators found that diabetes patients were
more likely to have lower socioeconomic status than non-
diabetics, and in poor urban Kenyan communities the
prevalence of diabetes was 5% [46], the level comparable
with prevalence in the general population in SSA [1]. The
popular belief in some SSA settings is that diabetes is the
disease of people from high social classes because they are
prone to diabetes risk factors like obesity and physical in-
activity unlike those in low social economic class. By con-
trast, findings from this study and previous reports
suggest that the prevalence of non-communicable diseases
in poor people including those with HIV in SSA is likely
to be higher, and efforts to control these diseases should
not neglect these populations.
The main limitation of the study was that it was con-
ducted among patients who had BMI less than 18.5 (kg/
m2) at ART initiation, so it may not be possible to ex-
trapolate our results to those not malnourished at the start
of ART, but this does not reduce the external validity of
our findings since a sizeable proportion of patients start-
ing ART in Tanzania are undernourished [9]. In the
present study we were not able to follow-up 58.1% of 704
patients enrolled in NUSTART trial. Of those not seen
66% (286) had died before follow-up and 34% (145) were
not traceable, had declined to participate or had travelled.
Those not traceable, declined or travelled were similar in
baseline body mass index and fat mass index as those
followed-up and therefore are likely to have the same
prevalence of pre-diabetes or diabetes as those followed-
up. However, those died had lower body mass index and
fat mass index. As explained above, since low body mass
index and fat mass index are predictors of of pre-diabetes
and diabetes in this cohort it is possible that those died
had higher prevalence of glucose dysglycemia than the co-
hort followed-up. Therefore, the prevalence of pre-
diabetes and diabetes we report may be an underestimate
of the true burden of dysglycemia among undernourished
HIV patients at ART initiation in this setting.
This was a cross-sectional study, so it is difficult to
conclude the directionality of predictors and study out-
come, although it is unlikely that pre-diabetes should
lead to low fat reserve. Moreover, we did not have an
HIV-negative control group or an HIV-infected but ART
naive group which would have helped to disentangle the
role of HIV and ART in the occurrence of pre-diabetes
and diabetes in this population.
Regarding predictors, we found CRP and CD4 count were
not predictors of pre-diabetes and diabetes. However, CRP
is non-specific marker of inflammation and CD4 counts
may not be a good marker HIV progression in malnour-
ished patients [47]. Future studies should explore the associ-
ation of inflammation with pre-diabetes and diabetes using
more specific inflammatory markers like Interleukin 6 (IL-6)
and use viral load as marker of severity of HIV infection in
assessing predictors of dysglycemia among HIV patients.
Conclusions
In this study we found that in HIV-infected adults on ART
who were malnourished at ART initiation 2–3 years earlier,
low adiposity at both baseline and follow-up were associ-
ated with increased likelihood of having pre-diabetes and
diabetes. Surprisingly, CRP was not a predictor. Further
studies in general HIV-infected populations are needed to
confirm these findings and to further investigate the role of
body composition, HIV, ART, and inflammation in the
pathogenesis of diabetes among HIV-infected populations
in order to improve the evidence base for developing inter-
ventions to reduce diabetes risk in this population.
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